Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995045426> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2995045426 endingPage "S619" @default.
- W2995045426 startingPage "S619" @default.
- W2995045426 abstract "To evaluate the cost-effectiveness of tofacitinib for the treatment of moderate-to-severe active ulcerative colitis (UC) after failure or intolerance to a first line of biologic treatment, from the Spanish National Health System perspective. A lifetime Markov model with eight-week cycle duration was developed including four health states: remission, response, active UC and remission after surgery. Three scenarios were defined to compare tofacitinib versus adalimumab, infliximab and vedolizumab after failure/intolerance to a biologic drug (bio-experienced population). A multinomial network meta-analysis (NMA) was conducted to determine transition probabilities at both induction and maintenance phases. Utility values for each health state were extracted from literature. Each treatment’s posology was extracted from its summary of product characteristics. Direct costs were considered (€, 2019): drug acquisition costs (ex-factory price with mandatory deductions), administration, surgery, patient management and adverse event costs. Local unitary costs were applied from national databases. A 3% discount rate was applied to costs and outcomes. A €25,000€/quality-adjusted life-years (QALY) threshold value was considered. Probabilistic sensitivity analyses (PSA) were conducted. Tofactinib is a dominant treatment and generates cost savings of €2,890.91 vs infliximab and €11,437.56 vs vedolizumab; with small QALY differences (<0.05). Compared to adalimumab, tofacitinib generates small QALY gains (0.09) and presents slight incremental costs (€961.68), mostly due to a lower efficacy of adalimumab (NMA) that would cause an increased treatment discontinuation and thereby reduce pharmaceutical costs. PSA showed that tofacitinib has a probability of being cost-effective of 59.70% vs adalimumab, and over 74% vs infliximab and vedolizumab. According to the analysis results, after failure or intolerance to biologic therapy, tofacitinib is a cost-saving therapy for the treatment of bio-experienced moderate-to-severe UC patients with similar QALY gains vs infliximab and vedolizumab. Besides, it is a cost-effective alternative when compared to adalimumab (incremental cost-effectiveness ratio: €10,567.21/QALY)." @default.
- W2995045426 created "2019-12-26" @default.
- W2995045426 creator A5001644383 @default.
- W2995045426 creator A5006883948 @default.
- W2995045426 creator A5008963665 @default.
- W2995045426 creator A5013238742 @default.
- W2995045426 creator A5018464239 @default.
- W2995045426 creator A5029938660 @default.
- W2995045426 creator A5032918584 @default.
- W2995045426 creator A5041580345 @default.
- W2995045426 creator A5049752247 @default.
- W2995045426 creator A5063131519 @default.
- W2995045426 creator A5072568679 @default.
- W2995045426 date "2019-11-01" @default.
- W2995045426 modified "2023-09-27" @default.
- W2995045426 title "PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN" @default.
- W2995045426 doi "https://doi.org/10.1016/j.jval.2019.09.1139" @default.
- W2995045426 hasPublicationYear "2019" @default.
- W2995045426 type Work @default.
- W2995045426 sameAs 2995045426 @default.
- W2995045426 citedByCount "1" @default.
- W2995045426 countsByYear W29950454262020 @default.
- W2995045426 crossrefType "journal-article" @default.
- W2995045426 hasAuthorship W2995045426A5001644383 @default.
- W2995045426 hasAuthorship W2995045426A5006883948 @default.
- W2995045426 hasAuthorship W2995045426A5008963665 @default.
- W2995045426 hasAuthorship W2995045426A5013238742 @default.
- W2995045426 hasAuthorship W2995045426A5018464239 @default.
- W2995045426 hasAuthorship W2995045426A5029938660 @default.
- W2995045426 hasAuthorship W2995045426A5032918584 @default.
- W2995045426 hasAuthorship W2995045426A5041580345 @default.
- W2995045426 hasAuthorship W2995045426A5049752247 @default.
- W2995045426 hasAuthorship W2995045426A5063131519 @default.
- W2995045426 hasAuthorship W2995045426A5072568679 @default.
- W2995045426 hasBestOaLocation W29950454261 @default.
- W2995045426 hasConcept C126322002 @default.
- W2995045426 hasConcept C197934379 @default.
- W2995045426 hasConcept C2776207728 @default.
- W2995045426 hasConcept C2777138892 @default.
- W2995045426 hasConcept C2777575956 @default.
- W2995045426 hasConcept C2778715236 @default.
- W2995045426 hasConcept C2778886723 @default.
- W2995045426 hasConcept C2779134260 @default.
- W2995045426 hasConcept C2780132546 @default.
- W2995045426 hasConcept C2780479503 @default.
- W2995045426 hasConcept C71924100 @default.
- W2995045426 hasConceptScore W2995045426C126322002 @default.
- W2995045426 hasConceptScore W2995045426C197934379 @default.
- W2995045426 hasConceptScore W2995045426C2776207728 @default.
- W2995045426 hasConceptScore W2995045426C2777138892 @default.
- W2995045426 hasConceptScore W2995045426C2777575956 @default.
- W2995045426 hasConceptScore W2995045426C2778715236 @default.
- W2995045426 hasConceptScore W2995045426C2778886723 @default.
- W2995045426 hasConceptScore W2995045426C2779134260 @default.
- W2995045426 hasConceptScore W2995045426C2780132546 @default.
- W2995045426 hasConceptScore W2995045426C2780479503 @default.
- W2995045426 hasConceptScore W2995045426C71924100 @default.
- W2995045426 hasLocation W29950454261 @default.
- W2995045426 hasOpenAccess W2995045426 @default.
- W2995045426 hasPrimaryLocation W29950454261 @default.
- W2995045426 hasRelatedWork W2006826205 @default.
- W2995045426 hasRelatedWork W2042655884 @default.
- W2995045426 hasRelatedWork W2105263940 @default.
- W2995045426 hasRelatedWork W2152399325 @default.
- W2995045426 hasRelatedWork W2944282858 @default.
- W2995045426 hasRelatedWork W2995236676 @default.
- W2995045426 hasRelatedWork W3147462706 @default.
- W2995045426 hasRelatedWork W4205274317 @default.
- W2995045426 hasRelatedWork W4210933462 @default.
- W2995045426 hasRelatedWork W4213385218 @default.
- W2995045426 hasVolume "22" @default.
- W2995045426 isParatext "false" @default.
- W2995045426 isRetracted "false" @default.
- W2995045426 magId "2995045426" @default.
- W2995045426 workType "article" @default.